Watson Confirms Lo Loestrin® Fe Patent Challenge - MarketWatch (press release)
Watson Confirms Lo Loestrin® Fe Patent ChallengeMarketWatch (press release).
Watson confirms filing of ANDA for generic version of Lo Loestrin Fe with FDA - Pharmaceutical Business Review
Watson confirms filing of ANDA for generic version of Lo Loestrin Fe with FDAPharmaceutical Business ReviewWatson Pharmaceuticals has confirmed the filing of ANDA with FDA by Watson Laboratories seeking approval to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and Ferrous Fumarate Tablets, 1mg/0.
Lilly, Jaguar Land Rover, Viacom: Intellectual Property - BusinessWeek
Lilly, Jaguar Land Rover, Viacom: Intellectual PropertyBusinessWeekLo Loestrin Fe contains the active ingredients norethindrone acetate and ethinyl estradiol.
Lilly, Jaguar Land Rover, Viacom: Intellectual Property - Bloomberg
Lilly, Jaguar Land Rover, Viacom: Intellectual PropertyBloombergLo Loestrin Fe contains the active ingredients norethindrone acetate and ethinyl estradiol.
Perrigo Announces FDA Final Approval and Launch of OTC Lansoprazole; Watson ... - BioMedReports (subscription)
Perrigo Announces FDA Final Approval and Launch of OTC Lansoprazole; Watson .
us